Immunonutrition and Quality of Life of Cancer Patients Undergoing Oncological Treatment

NCT ID: NCT01423799

Last Updated: 2015-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the health-related quality of life following dietary supplementation with an immunonutrition formulation vs an isocaloric/isoprotein control diet supplement in patients suffering from upper digestive tract neoplasia undergoing oncological treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastrointestinal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nutritional product

Nutritional intervention containing immuno-nutrients

Group Type EXPERIMENTAL

Nutritional supplements containing arginine, n-3 and nucleotides

Intervention Type DIETARY_SUPPLEMENT

Nutritional intervention with immuno-nutrients

Control Group

Isocaloric and isonitrogenous control without immuno nutrients.

Group Type ACTIVE_COMPARATOR

Isocaloric control

Intervention Type DIETARY_SUPPLEMENT

Isocaloric and isonitrogenous control without immuno nutrients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nutritional supplements containing arginine, n-3 and nucleotides

Nutritional intervention with immuno-nutrients

Intervention Type DIETARY_SUPPLEMENT

Isocaloric control

Isocaloric and isonitrogenous control without immuno nutrients

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven GI cancer.
* Age ≥ 18 years.
* Life expectancy more than 3 months.
* Female patients of child-bearing potential must be willing to employ effective contraception during the study period.
* Female patients of child-bearing potential must have a negative serum Beta Human Chorionic Gonadotrophin (βhCG) test at Visit 0.
* The patient is able to communicate effectively with study personnel and is considered reliable, willing, and cooperative in terms of compliance with the protocol requirements.
* The patient voluntarily gives written informed consent to participate in the study.

Exclusion Criteria

* Severe concomitant clinical conditions other than the previously untreated digestive tract cancer that jeopardise the protocol follow-up.
* The patient is pregnant or is a lactating woman.
* Currently participating or having participated in another interventional clinical trial related to nutritional support during the 30 days prior to the beginning of the study product intake, except if this other interventional trial is testing new drug or surgical intervention. (Note: participation in a prior or concurrent clinical trial not related to nutritional support does not exclude the patient from participation.)
* Other malignancies in the last 5 years (except for successfully treated in situ basocellular skin and in situ cervical uterine tumours).
* Patients with more than 20% weight loss over a 6 months period.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Société des Produits Nestlé (SPN)

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christophe Mariette, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Claude Huriez, CHRU-Place de Verdun-59037 Lille, Cedex France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Régional Universitaire de Lille

Lille, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

09.54.CLI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nutrition Impact on Immunotherapy of Cancer
NCT06500234 RECRUITING PHASE3